Korsana Biosciences, Inc. Common Stock
KRSA
30 hedge funds and large institutions have $8.95M invested in Korsana Biosciences, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 11 reducing their positions, and 5 closing their positions.
14,700% more call options, than puts
Call options by funds: $148K | Put options by funds: $1K
0.49% less ownership
Funds ownership: 47.89% → 47.4% (-0.49%)
9% less funds holding
Funds holding: 33 → 30 (-3)
35% less capital invested
Capital invested by funds: $13.7M → $8.95M (-$4.72M)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
64% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$26.4K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.36K |
| 3 |
PIM
Penobscot Investment Management
Boston,
Massachusetts
|
+$896 |
| 4 |
Morgan Stanley
New York
|
+$795 |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$492 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$32K |
| 2 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
-$19.4K |
| 3 |
Jane Street
New York
|
-$16.7K |
| 4 |
Renaissance Technologies
New York
|
-$8.73K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.75K |
KRSA Hedge Fund Activity: Q1 2023 in Review
30 of the 6,284 institutional investors tracked by Wall St. Rank reported a position in Korsana Biosciences, Inc. Common Stock (KRSA) for Q1 2023, worth a combined $8.95M — down 35% from $13.7M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of KRSA and 3 opened new positions — a net loss of 2 holders — while 11 trimmed existing stakes and 4 added.
The largest buyer was CAPTRUST Financial Advisors, opening a new position worth an estimated $26.4K. The largest seller was Virtu Financial, exiting entirely with an estimated $32K sold.
- 30 institutional investors held Korsana Biosciences, Inc. Common Stock (KRSA) as of Q1 2023, down from 33 in Q4 2022.
- Funds reported $8.95M of Korsana Biosciences, Inc. Common Stock stock for Q1 2023, down 35% quarter-over-quarter.
- 3 funds opened new Korsana Biosciences, Inc. Common Stock positions in Q1 2023 and 5 closed out, a net change of -2 holders.
- The largest Korsana Biosciences, Inc. Common Stock buyer in Q1 2023 was CAPTRUST Financial Advisors, an estimated $26.4K added.
- The largest Korsana Biosciences, Inc. Common Stock seller in Q1 2023 was Virtu Financial, an estimated $32K sold.
Based on aggregated 13F filings for Q1 2023.